- $135.55m
- $118.16m
- $27.47m
Cue Biopharma Inc expected to post a loss of 15 cents a share - Earnings Preview
Cue Biopharma Inc expected to post a loss of 15 cents a share - Earnings Preview
Brief: Cue Biopharma Prices Common Stock And Warrants At $0.79 Per Share; Pre-Funded Warrants At $0.789
Brief: Boehringer Ingelheim, Cue Biopharma Partner To Develop Autoimmune And Inflammatory Disease Treatments
Cue Biopharma Inc reports results for the quarter ended December 31 - Earnings Summary
Cue Biopharma Inc expected to post a loss of 16 cents a share - Earnings Preview
Cue Biopharma Inc expected to post a loss of 16 cents a share - Earnings Preview
Cue Biopharma Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Cue Biopharma Announces Strategic Organizational Transition
Brief: Cue Biopharma Inc Enters Second Amendment To Loan Agreement With Svb
U.S. RESEARCH ROUNDUP-Coca-Cola Co, Estée Lauder, Quanta Services
Brief: Cue Biopharma Announces Proposed Public Offering
U.S. RESEARCH ROUNDUP-Alexander & Baldwin, Instructure Holdings, RPM International
Brief: Cue Biopharma To Slash 25% Workforce
Brief: Cue Biopharma Presents Updated Data from Phase 1 Trial of CUE-101 in Recurrent/Metastatic HPV+ Head and Neck Cancer at the 2024 ASCO Annual Meeting
Cue Biopharma Inc reports results for the quarter ended in January - Earnings Summary
Cue Biopharma Inc expected to post a loss of 28 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-CME Group, Danimer Scientific, Intercontinental Exchange
Cue Biopharma Inc reports results for the quarter ended in December - Earnings Summary